CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

Apr 16 2010NewsGuard 100/100 Score

CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that preclinical data on its discovery of novel synergistic drug combinations for the treatment of cancer will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC. These preclinical studies reinforce the rationale for investigation of A2A and β2AR agonists in the treatment of multiple myeloma and other B-cell malignancies and highlight the power of the CombinatoRx combination high throughput screening (cHTS™) technology to interrogate combination activity across large panels of cancer cells to identify novel mechanisms for therapeutic application.

“Identification of synergistic drugs using combination high-throughput screening”

Poster Presentation:

  • Abstract #5509: Wednesday, April 21, 2010, 8:00 AM - 11:00 AM, "Identification of synergistic drugs using combination high-throughput screening," Rickles, et.al., Exhibit Hall A-C, Poster Section 25, , Poster Board 29.
Source:

CombinatoRx, Incorporated.

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Study shows cannabis as a genotoxic substance with cancer risks
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy
How different types of bread impact cancer risk
Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients
Innovative urine test could improve pancreatic cancer survival rates
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients
Golgi apparatus plays crucial role in enhancing T-cell function against cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Air pollution linked to head and neck cancer risk